Literature DB >> 19245906

The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.

Jason W Smith1, Jonathan Moreira, Gerard Abood, Gerard V Aranha, Suneel Nagda, Robert H Wagner, Margo Shoup.   

Abstract

BACKGROUND: The influence of positron emission tomography (PET) scanning with flourodeoxyglucose (FDG) on decision making for the treatment of patients with esophagogastric junction (EGJ) carcinoma is unclear as is the utility of the maximum standardized uptake value (SUV) as a prognostic indicator.
METHODS: This study was a retrospective review of EGJ carcinoma cases at a single institution during a 5-year period.
RESULTS: FDG-PET altered treatment in 13 of 64 patients (20%). Of these, 21 patients had PET scans before and after undergoing neoadjuvant chemoradiation (CRT) as well as surgery. Patients who had a decrease in SUV >50% had a 12-month disease-free survival advantage over patients a decrease in SUV <50% (93% vs 43%, P = .025).
CONCLUSIONS: FDG-PET alters treatment in a significant number of patients with EGJ carcinoma. A >50% decrease in SUV after CRT is associated with an improved prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245906     DOI: 10.1016/j.amjsurg.2008.10.010

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

Review 1.  [Importance of PET in surgery of esophageal cancer].

Authors:  K Ott; T Schmidt; F Lordick; K Herrmann
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

Review 2.  Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.

Authors:  W Zhu; L Xing; J Yue; X Sun; X Sun; H Zhao; J Yu
Journal:  Br J Radiol       Date:  2012-02-14       Impact factor: 3.039

3.  Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.

Authors:  Xavier Cuenca; Christophe Hennequin; Elif Hindié; Sofia Rivera; Laetitia Vercellino; Valérie Baruch-Hennequin; Jean-Marc Gornet; Pierre Cattan; Mircea Chirica; Laurent Quéro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-01       Impact factor: 9.236

4.  18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy.

Authors:  Masahiko Yano; Hiroshi Miyata; Keijiro Sugimura; Masaaki Motoori; Takeshi Omori; Yoshiyuki Fujiwara; Norikatsu Miyoshi; Masayoshi Yasui; Masayuki Ohue; Hirofumi Akita; Akira Tomokuni; Hidenori Takahashi; Shogo Kobayashi; Masato Sakon
Journal:  Mol Clin Oncol       Date:  2018-01-10

5.  Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Authors:  R S Gillies; M R Middleton; C Blesing; K Patel; N Warner; R E K Marshall; N D Maynard; K M Bradley; F V Gleeson
Journal:  Eur Radiol       Date:  2012-05-05       Impact factor: 5.315

6.  Prognostic significance of autophagy-related genes within esophageal carcinoma.

Authors:  Chongxiang Chen; Siliang Chen; Huijiao Cao; Jiaojiao Wang; Tianmeng Wen; Xiaochun Hu; Huan Li
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.